Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Neovascular (Wet) AMD
In brief
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Key facts
- Study ID
- NCT06550011
- Run by
- Avirmax Biopharma Inc
- People needed
- 18
- Starts
- 2024-08-07
- Expected to finish
- 2031-01-16
- Last updated by the study team
- 2026-02-12
Who can join
Age: 50 and older, up to 89. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Retina Consultants — Bakersfield, California, United States
- Bay Area Retina Associates — Walnut Creek, California, United States
- Retina Consultants of Texas - San Antonio — San Antonio, Texas, United States
- Retina Consultants of Texas — The Woodlands, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.